Europe is becoming less attractive for pharmaceutical innovation after two decades of declining R&D investment, says pharma industry leader
Europe needs a much more coordinated discussion on how it values medicines and innovation if it wants to withstand mounting geopolitical and trade pressures, argues Nathalie Moll, director general of the European Federation of Pharmaceutical Industries and Associations.
Speaking with Euractiv, Moll said Europe’s longstanding focus on lowering medicine costs has left the region struggling to compete with the US and China.
While she described the forthcoming Biotech Act as “a great first step”, she warned that reversing Europe’s decline in research and development investment would require sustained structural reform, stronger action at the member-state level, and a rethink of how healthcare systems allocate resources.
Europe’s declining attractiveness
